Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.

Autor: Smith AL; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA., Pal D; College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, CA, USA., Martinez-Rico R; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA., Eiken AP; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA., Durden DL; College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, CA, USA., Kutateladze TG; Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA., El-Gamal D; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2023 Dec; Vol. 64 (14), pp. 2333-2337. Date of Electronic Publication: 2023 Sep 14.
DOI: 10.1080/10428194.2023.2256914
Databáze: MEDLINE